Literature DB >> 27832840

The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths.

Sunny X Tang1, Tyler M Moore2, Monica E Calkins2, James J Yi3, Adam Savitt2, Christian G Kohler2, Margaret C Souders4, Elaine H Zackai5, Donna M McDonald-McGinn5, Beverly S Emanuel5, Ruben C Gur2, Raquel E Gur3.   

Abstract

BACKGROUND: Chromosome 22q11.2 deletion syndrome (22q11DS) is a promising model for studying psychosis risk. Direct comparisons of psychosis features between 22q11DS and nondeleted (ND) individuals are limited by inconsistency and small samples. In the largest study to date, we compare 22q11DS to ND in comorbidities, functioning, cognition, and psychosis features across the full range of overall severity.
METHODS: ND youths (n = 150) ages 9 to 24 years were matched to 22q11DS individuals (n = 150) on age and sex, stratifying for presence of psychosis spectrum disorder. Individuals were evaluated for psychosis using the Structured Interview for Prodromal Syndromes, and for attention-deficit/hyperactivity, substance-related, and mood disorders. Differential item functioning analysis addressed whether 22q11DS differs from ND in the probability of clinically significant ratings while holding constant the overall level of psychosis.
RESULTS: Onset of psychosis proneness was similar among 22q11DS (mean: 11.0 years) and ND (mean: 12.1 years) individuals. Accounting for higher overall psychosis symptoms, 22q11DS participants were still more likely to manifest impaired stress tolerance, avolition, and ideational richness; ND individuals were more likely to exhibit unusual thoughts, persecutory ideas, and bizarre thinking. Cognition was impaired in 22q11DS, but it did not correlate with symptoms except ideational richness. Comorbid anxiety disorders were more likely in psychosis spectrum 22q11DS; substance-related disorders were more likely in ND. Global assessment of function was similar in 22q11DS and ND individuals, except among those with low total Structured Interview for Prodromal Syndromes scores.
CONCLUSIONS: Individuals with 22q11DS share overarching similarities with ND individuals in psychosis symptoms and age of onset for psychosis proneness; this continues to support the 22q11DS model as a valuable window into mechanisms contributing to psychosis.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  22q11.2 Deletion syndrome; Clinical high risk; DiGeorge syndrome; Prodromal; Psychosis; Schizophrenia

Mesh:

Year:  2016        PMID: 27832840      PMCID: PMC5342951          DOI: 10.1016/j.biopsych.2016.08.034

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  44 in total

1.  Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.

Authors:  Doron Gothelf; Amanda J Law; Amos Frisch; Jingshan Chen; Omer Zarchi; Elena Michaelovsky; Renee Ren-Patterson; Barbara K Lipska; Miri Carmel; Bhaskar Kolachana; Abraham Weizman; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

2.  Subthreshold psychotic symptoms in 22q11.2 deletion syndrome.

Authors:  Sunny X Tang; James J Yi; Tyler M Moore; Monica E Calkins; Christian G Kohler; Daneen A Whinna; Margaret C Souders; Elaine H Zackai; Donna M McDonald-McGinn; Beverly S Emanuel; Warren B Bilker; Ruben C Gur; Raquel E Gur
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-19       Impact factor: 8.829

Review 3.  Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5.

Authors:  Deanna M Barch; Juan Bustillo; Wolfgang Gaebel; Raquel Gur; Stephan Heckers; Dolores Malaspina; Michael J Owen; Susan Schultz; Rajiv Tandon; Ming Tsuang; Jim Van Os; William Carpenter
Journal:  Schizophr Res       Date:  2013-05-22       Impact factor: 4.939

4.  Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning.

Authors:  Marco Armando; Paolo Girardi; Stefano Vicari; Deny Menghini; Maria Cristina Digilio; Maria Pontillo; Riccardo Saba; Luigi Mazzone; Ashleigh Lin; Claudia M Klier; Miriam R Schäfer; G Paul Amminger
Journal:  Schizophr Res       Date:  2012-05-23       Impact factor: 4.939

5.  Neurocognitive development in 22q11.2 deletion syndrome: comparison with youth having developmental delay and medical comorbidities.

Authors:  R E Gur; J J Yi; D M McDonald-McGinn; S X Tang; M E Calkins; D Whinna; M C Souders; A Savitt; E H Zackai; P J Moberg; B S Emanuel; R C Gur
Journal:  Mol Psychiatry       Date:  2014-01-21       Impact factor: 15.992

Review 6.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

7.  Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries.

Authors:  Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Schizophr Res       Date:  2012-03-31       Impact factor: 4.939

8.  Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome.

Authors:  Joel Stoddard; Tara Niendam; Robert Hendren; Cameron Carter; Tony J Simon
Journal:  Schizophr Res       Date:  2010-01-06       Impact factor: 4.939

9.  The schizophrenia phenotype in 22q11 deletion syndrome.

Authors:  Anne S Bassett; Eva W C Chow; Philip AbdelMalik; Mirona Gheorghiu; Janice Husted; Rosanna Weksberg
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

10.  Neurocognitive growth charting in psychosis spectrum youths.

Authors:  Ruben C Gur; Monica E Calkins; Theodore D Satterthwaite; Kosha Ruparel; Warren B Bilker; Tyler M Moore; Adam P Savitt; Hakon Hakonarson; Raquel E Gur
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

View more
  19 in total

1.  Early language measures associated with later psychosis features in 22q11.2 deletion syndrome.

Authors:  Cynthia B Solot; Tyler M Moore; Terrence Blaine Crowley; Marsha Gerdes; Edward Moss; Daniel E McGinn; Beverly S Emanuel; Elaine H Zackai; Sean Gallagher; Monica E Calkins; Kosha Ruparel; Ruben C Gur; Donna M McDonald-McGinn; Raquel E Gur
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2020-07-27       Impact factor: 3.568

2.  Animal Models of Developmental Neuropathology in Schizophrenia.

Authors:  Nickole Kanyuch; Stewart Anderson
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 3.  The SERCA2: A Gatekeeper of Neuronal Calcium Homeostasis in the Brain.

Authors:  Aikaterini Britzolaki; Joseph Saurine; Emily Flaherty; Connor Thelen; Pothitos M Pitychoutis
Journal:  Cell Mol Neurobiol       Date:  2018-04-16       Impact factor: 5.046

4.  Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.

Authors:  Maria Niarchou; Monica E Calkins; Tyler M Moore; Sunny X Tang; Donna M McDonald-McGinn; Elaine H Zackai; Beverly S Emanuel; Ruben C Gur; Raquel E Gur
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

5.  White matter microstructural deficits in 22q11.2 deletion syndrome.

Authors:  David R Roalf; J Eric Schmitt; Simon N Vandekar; Theodore D Satterthwaite; Russell T Shinohara; Kosha Ruparel; Mark A Elliott; Karthik Prabhakaran; Donna M McDonald-McGinn; Elaine H Zackai; Ruben C Gur; Beverly S Emanuel; Raquel E Gur
Journal:  Psychiatry Res Neuroimaging       Date:  2017-08-24       Impact factor: 2.376

6.  Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome.

Authors:  Marco Armando; Corrado Sandini; Maelle Chambaz; Marie Schaer; Maude Schneider; Stephan Eliez
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

7.  Olfactory deficits and psychosis-spectrum symptoms in 22q11.2 deletion syndrome.

Authors:  Sunny X Tang; Paul J Moberg; James J Yi; Andrew S Wiemken; Erich M Dress; Tyler M Moore; Monica E Calkins; Donna M McDonald-McGinn; Elaine H Zackai; Beverly S Emanuel; Ruben C Gur; Raquel E Gur; Bruce I Turetsky
Journal:  Schizophr Res       Date:  2018-07-11       Impact factor: 4.939

8.  Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study.

Authors:  Omri Weisman; Yael Guri; Raquel E Gur; Donna M McDonald-McGinn; Monica E Calkins; Sunny X Tang; Beverly Emanuel; Elaine H Zackai; Stephan Eliez; Maude Schneider; Marie Schaer; Wendy R Kates; Kevin M Antshel; Wanda Fremont; Vandana Shashi; Stephen R Hooper; Marco Armando; Stefano Vicari; Maria Pontillo; Leila Kushan; Maria Jalbrzikowski; Carrie E Bearden; Joseph F Cubells; Opal Y Ousley; Elaine F Walker; Tony J Simon; Joel Stoddard; Tara A Niendam; Marianne B M van den Bree; Doron Gothelf
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

Review 9.  Pathways to understanding psychosis through rare - 22q11.2DS - and common variants.

Authors:  Raquel E Gur; David R Roalf; Aaron Alexander-Bloch; Donna M McDonald-McGinn; Ruben C Gur
Journal:  Curr Opin Genet Dev       Date:  2021-02-08       Impact factor: 5.578

Review 10.  Psychosis Risk and Development: What Do We Know From Population-Based Studies?

Authors:  Eva Mennigen; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2019-12-20       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.